EMA Opinion: Xervyteg (allogeneic faecal microbiota, pooled) — MaaT PHARMA

View source ↗

Summary

EMA opinion on Xervyteg (allogeneic faecal microbiota, pooled) for graft-versus-host disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Xervyteg (allogeneic faecal microbiota, pooled)

Snippet

Status: Opinion. Therapeutic area: Graft vs Host Disease. MAH: MaaT PHARMA. Decision date: 25/06/2026